{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:54:53Z","timestamp":1765486493468,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swiss National Science Professorship","award":["PP00P3_157448"],"award-info":[{"award-number":["PP00P3_157448"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.omto.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T01:34:41Z","timestamp":1602293681000},"page":"179-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses"],"prefix":"10.1016","volume":"19","author":[{"given":"Sandra S.","family":"Ring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3196-143X","authenticated-orcid":false,"given":"Micha\u0142","family":"Kr\u00f3lik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Hasan Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Ludewig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2020.10.001_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2020.10.001_bib2","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1001\/jama.284.23.3040","article-title":"Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls","volume":"284","author":"Chang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.omto.2020.10.001_bib3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omto.2020.10.001_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/B978-0-12-800249-0.00002-0","article-title":"Therapeutic cancer vaccines","volume":"121","author":"Schlom","year":"2014","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.omto.2020.10.001_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omto.2020.10.001_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00262-013-1400-3","article-title":"Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients","volume":"62","author":"Morse","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2020.10.001_bib8","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T\u00a0cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib10","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.ymthe.2017.07.012","article-title":"Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations","volume":"25","author":"Wingerath","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.10.001_bib11","article-title":"A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus","author":"Schwendinger","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omto.2020.10.001_bib12","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.188.2.277","article-title":"gp100\/pmel 17 is a murine tumor rejection antigen: induction of \u201cself\u201d-reactive, tumoricidal T\u00a0cells using high-affinity, altered peptide ligand","volume":"188","author":"Overwijk","year":"1998","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib14","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1002\/jgm.496","article-title":"Adenoviral vectors for gene transfer and therapy","volume":"6","author":"Volpers","year":"2004","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omto.2020.10.001_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-3389-1_24","article-title":"Generation of lymphocytic choriomeningitis virus based vaccine vectors","volume":"1404","author":"Ring","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omto.2020.10.001_bib16","first-page":"289","article-title":"Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy","volume":"20","author":"Phan","year":"2013","journal-title":"Cancer Contr."},{"key":"10.1016\/j.omto.2020.10.001_bib17","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.10.001_bib18","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","article-title":"Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines","volume":"14","author":"Smith","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.10.001_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omto.2020.10.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.124405","article-title":"An effective mouse model for adoptive cancer immunotherapy targeting neoantigens","volume":"4","author":"Hanada","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2020.10.001_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib22","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T\u00a0cells","volume":"198","author":"Overwijk","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib25","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","article-title":"Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in\u00a0vivo tumor regression","volume":"154","author":"Kawakami","year":"1995","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2020.10.001_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.omto.2020.10.001_bib27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor","volume":"3","author":"T\u00e4htinen","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2020.10.001_bib28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<532::AID-IJC16>3.0.CO;2-K","article-title":"Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity","volume":"83","author":"Yang","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2020.10.001_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"10.1016\/j.omto.2020.10.001_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.omto.2020.10.001_bib32","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1158\/0008-5472.CAN-06-4317","article-title":"Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus","volume":"67","author":"Bourbeau","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.10.001_bib33","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1128\/JVI.00599-12","article-title":"Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates","volume":"86","author":"Flatz","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2020.10.001_bib34","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1073\/pnas.1013084108","article-title":"Single-cell gene-expression profiling reveals qualitatively distinct CD8 T\u00a0cells elicited by different gene-based vaccines","volume":"108","author":"Flatz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.10.001_bib35","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1158\/1078-0432.CCR-05-2061","article-title":"Evaluation of prime\/boost regimens using recombinant poxvirus\/tyrosinase vaccines for the treatment of patients with metastatic melanoma","volume":"12","author":"Lindsey","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.10.001_bib36","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4049\/jimmunol.1101138","article-title":"Melanoma Cells and Prevent Autochthonous Mouse T Boost Generate High-Quality CD8 Memory Lentivector Prime and Vaccinia Virus Vector","volume":"187","author":"Guo","year":"2011","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.omto.2020.10.001_bib37","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cncr.21669","article-title":"Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100","volume":"106","author":"Spaner","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.omto.2020.10.001_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CJI.0000000000000208","article-title":"Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice","volume":"41","author":"Aitken","year":"2018","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib39","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.3390\/vaccines4040044","article-title":"Homologous prime-boost vaccination with OVA entrapped in self-adjuvanting archaeosomes induces high numbers of OVA-specific CD8+ T\u00a0cells that protect against subcutaneous B16-OVA melanoma","volume":"4","author":"Stark","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omto.2020.10.001_bib40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T\u00a0cells","volume":"155","author":"North","year":"1982","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2020.10.001_bib41","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.10.001_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fonc.2019.00279","article-title":"Turning the tide against regulatory T\u00a0cells","volume":"9","author":"Han","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2020.10.001_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00262-012-1322-5","article-title":"Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine","volume":"62","author":"Peng","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib44","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood.V95.1.212","article-title":"Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice","volume":"95","author":"Angulo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.10.001_bib45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/CJI.0b013e318255585a","article-title":"Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors","volume":"35","author":"Miky\u0161kov\u00e1","year":"2012","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib46","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2009-11-253336","article-title":"Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype","volume":"115","author":"Ding","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.10.001_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellimm.2016.08.006","article-title":"Improvement of anti-tumor immunity of fibroblast activation protein \u03b1 based vaccines by combination with cyclophosphamide in a murine model of breast cancer","volume":"310","author":"Xia","year":"2016","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omto.2020.10.001_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.cji.0000211311.28739.e3","article-title":"Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells","volume":"30","author":"Salem","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib49","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00262-012-1242-4","article-title":"Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial","volume":"61","author":"Ellebaek","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib50","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-013-1397-7","article-title":"Effects of cyclophosphamide and IL-2 on regulatory CD4+ T\u00a0cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T\u00a0cell response","volume":"62","author":"Camisaschi","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-015-1656-x","article-title":"Low-dose cyclophosphamide enhances antigen-specific CD4(+) T\u00a0cell responses to NY-ESO-1\/ISCOMATRIX\u2122 vaccine in patients with advanced melanoma","volume":"64","author":"Klein","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2020.10.001_bib52","doi-asserted-by":"crossref","first-page":"E670","DOI":"10.1002\/ijc.27388","article-title":"Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study","volume":"131","author":"Vermeij","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2020.10.001_bib53","doi-asserted-by":"crossref","first-page":"e1207842","DOI":"10.1080\/2162402X.2016.1207842","article-title":"mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma","volume":"5","author":"Borch","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.10.001_bib54","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1089\/104303400750001417","article-title":"Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production","volume":"11","author":"Schiedner","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2020.10.001_bib55","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/jvi.70.11.7498-7509.1996","article-title":"Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J.\u00a0Virol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:20:43Z","timestamp":1762496443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770520301522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":55,"alternative-id":["S2372770520301522"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2020.10.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"type":"print","value":"2372-7705"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}